Oramed Pharmaceuticals Stock Skyrockets On ORMD-0801 Results (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

As the global market value of treatments concerning diabetes currenty stands at US$41 billion, we would advise you to check out Oramed Pharmaceuticals Inc. ticker symbol ORMP. This Company’s (www.oramed.com) stock has skyrocketed +61.54% Up 4.40 generating over 2.3 million shares in the financial district at $11.55 per share Friday December 20, 2013 Real-time: 11:29AM EST. Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems. A global market currently valued at $49 billion expecting a 83.67% increase 2 years from now.

The HOT topic amongst investors surrounding Oramed Pharmaceuticals Inc. is its oral insulin capsule (ORMD-0801) in type 1 diabetes patients. Oramed Pharmaceuticals Inc. introduced ORMD-0801 to replace the mealtime (bolus) insulin doses, which would significantly reduce the number of daily injections. The Company announced today successful results in a clinical trial testing the pharmacokinetic dose response of its ORMD-0801 product. Patient responded positively correlated with administered ORMD-0801 doses.

*****

Amarin Corporation plc (NASDAQ:AMRN)

With the global cardiovascular therapeutics market expected to reach US$115.6 billion 3 years from now, we would advise you to check out Amarin Corporation plc ticker symbol AMRN. This Company’s (www.amarincorp.com) stock has surged +25.16% Up 0.40 generating over 19.3 million shares in the financial district at $1.99 per share Friday December 20, 2013 Real-time: 11:53AM EST. Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The HOT topic amongst investors surrounding Amarin Corporation plc is Vascepa(R).

Vascepa is currently FDA approved for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia. ThE Company announced today that the FDA does not expect to take action on Amarin’s supplemental new drug application (sNDA) for the proposed ANCHOR indication labeling expansion for Vascepa(R) (icosapent ethyl) capsules on the December 20, 2013 Prescription Drug User Fee Act goal date because Amarin’s request to re-instate the ANCHOR Special Protocol Assessment agreement remains under consideration with the FDA. Tock market investors are pleased with Amarin Corporation’s decision to continue to work with the FDA to pursue reinstatement of the ANCHOR SPA agreement and approval of the ANCHOR supplemental new drug application.

****

Other stock’s that need be mentioned on the Wall Street Financial District:

Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) $3.41 (+18.81%) Up 0.54 Friday December 20, 2013 Real-time: 12:14PM EST

Apricus Biosciences, Inc. (NASDAQ:APRI) $2.13 (+12.78%) Up 0.24 Friday December 20, 2013 Real-time: 12:12PM EST

Remember: Always do your homework and consult your own financial professional.

Read Full Disclaimer at http://crweselect.com/disclaimer/